English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

To ascertain the most effective approach in pregnancies complicated by mild intrahepatic cholestasis of pregnancy (mICP) by evaluating rates of adverse perinatal outcomes (APOs) and pathological placental findings. A total of 89 pregnancies complicated by mICP (defined as total serum bile acids (TSBAs) levels &lt;40 µmol/L) were included. One-drug (ursodeoxycholic acid [UDCA]) ( n  = 49, 55.1%) and combined (UDCA  plus  S-adenosyl methionine (SAMe)) ( n  = 40, 44.9%) therapies were compared. No differences were found in demographic, obstetric, and placental characteristics. In UDCA  plus  SAMe group, premature delivery was a common clinical decision (14.3 versus 25%,  p -value = .201), with increased rates of instrumental vaginal delivery (VD; 28.6 versus 40%,  p -value = .522), but similar cesarean section (CS) rates (26.5 versus 25%,  p -value = .498). Mean placental weight was comparable (UDCA, mean 595.7 g, SD 213.1 g versus UDCA  plus  SAMe, mean 586.4 g, SD 102.9 g,  p -value = .875). A total of 110 lesions were identified, 64 in 25 placentas of patients assigned to the UDCA and 46 in 15 placentas of patients managed by UDCA  plus  SAMe. Placental findings attributable to maternal malperfusion were found in 41/25 and 32/15 cases treated by UCDA and UDCA  plus  SAMe (165 versus 213%,  p -value = .774), pathological fetal vascular supply in 17/25 and 8/15 placentas (68 versus 53%,  p- value = .777), and inflammatory lesions in 6/25 and 6/15 cases (24 versus 40%,  p -value = .757). Pregnancies complicated by mICP and managed by UDCA alone present similar APO rates and placental histopathology if compared with those treated by UDCA  plus  SAMe, failing to recognize advantages in the combined therapy. Further prospective studies and data sharing from ongoing RTCs could drive changes in therapeutic plan.

the journal of maternal-fetal and neonatal medicine

Does mild intrahepatic cholestasis of pregnancy require an aggressive management? Evidence from a prospective observational study focused on adverse perinatal outcomes and pathological placental findings